2023 year to date and third-quarter sales results

Ipsen has published its year to date and third-quarter sales results on 26 October 2023 at 7am CET.

Press release

Please find here the YTD 2023 press release and here the Ipsen YTD sales highlights.

Presentation

Please find here the YTD 2023 sales presentation.

Webcast replay

A conference call and webcast for investors and analysts was held on 26 October 2023. A recording is available below.

Webcast replay

Speakers

David Loew

Chief Executive Officer

Aymeric Le Chatelier

Executive Vice President

Chief Financial Officer

Ipsen

Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,300 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

Contacts  

Investors

Craig Marks, Vice President, Investor Relations, +44 (0)7584 349 193
Nicolas Bogler, Senior Investor Relations Manager, +33 6 52 19 98 92  

Media

Amy Wolf, Vice President and Head of Corporate Brand Strategy and Communications, +41 79 576 07 23
Ioana Piscociu, Senior Manager, Global Media Relations, +33 6 69 09 12 96